Sareum Holdings plc (SAR) is a leading drug manufacturers—specialty & generic business based in the UK. It opened the day at 0.8625p after a previous close of 0.885p. During the day the price has varied from a low of 0.8306p to a high of 0.88p. The latest price was 0.84p (25 minute delay). Sareum is listed on the London Stock Exchange (LSE) and employs 2 staff. All prices are listed in pence sterling.
Since the stock market crash in March caused by coronavirus, Sareum's share price has had significant positive movement.
Its last market close was 0.755p, which is 51.66% up on its pre-crash value of 0.365p and 243.18% up on the lowest point reached during the March crash when the shares fell as low as 0.22p.
If you had bought £1,000 worth of Sareum shares at the start of February 2020, those shares would have been worth £635.91 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth £1,882.79.
|52-week range||0.22p - 1.1p|
|50-day moving average||0.7563p|
|200-day moving average||0.6122p|
|Wall St. target price||1.9p|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||-0.1p|
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|3 months (2020-06-23)||60.00%|
|6 months (2020-03-23)||229.41%|
|Gross profit TTM||£0|
|Return on assets TTM||-57.54%|
|Return on equity TTM||-89.3%|
|Market capitalisation||£25.4 million|
TTM: trailing 12 months
We're not expecting Sareum to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.
Over the last 12 months, Sareum's shares have ranged in value from as little as 0.22p up to 1.1p. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (LSE average) beta is 1, while Sareum's is 1.6512. This would suggest that Sareum's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Sareum Holdings plc engages in the discovery and development of therapeutic drugs to treat cancer and autoimmune diseases. It develops therapeutic drugs based on its Sareum Kinase Inhibitor Library drug discovery platform. The company's product pipeline includes Checkpoint Kinase 1, Aurora+FLT3 kinase, and TYK2 kinase. It has collaborations with Hebei Medical University Biomedical Engineering Center and Sierra Oncology, Inc. The company was founded in 2003 and is based in Cambridge, the United Kingdom.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.